Sero-epidemiology of chronic HBV infection in Burkina Faso

Chronic hepatitis B virus (HBV) infection is higly prevalent in Western African countries and, based on recent estimates, it is above 12% in Burkina Faso. However, country-specific epidemiologic information and biomarker data obtained from serological surveys are sparse and mostly based on particular population groups, e.g. blood donors or from specific age-groups. Furthermore, laboratory and diagnostic capacity is likely to be restricted and requires to be build up in order to collect epidemiologic data which allow to draw conclusions on diagnostic and treatment needs.

The study aims, for the first time, to estimate the chronic HBV prevalence and risks in Burkina Faso based on  > 4,000 representativly sampled individuals in the general population of the Nouna district in Burkina Faso. This will be done by conducting a field sero-epidemiologic survey that includes interviewing and blood collection and analyses. The field phase is running in 2017 after successful piloting and establishing of research capacity (e.g. SOPs etc.). Subsequently, collected data are to be merged into the existing household data bases and connected to anonymized results from the laboratory analyses on HBsAg in collected blood samples.

The project is intended to provide epidemiologic information on chronic hepatitis infection and thereby inform health policy on potential treatment and diagnostic needs. The project is conducted in an DZIF African Partner Institution and in the scopme of 2015 published WHO guidelines that address prevention, diagnosis, and treatment of chronic HBV infection in low-and middle-income countries.



University Hospital Heidelberg and CRSN Burkina Faso

Project Leaders

Prof. Dr. Gérard Krause
Head of Department for Epidemiology

Dr. Jördis Ott

Funding Agencies

DZIF – German Center for Infection Research

HZI - Helmholtz Centre for Infection Research

Beteiligte Gruppen

DruckenPer Mail versendenTeilen